Erectile dysfunction

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Fungal infection, Medical Subject Headings, Marketing, European Commission, Liver, INN, Nitrate, Woman, Allergy, PDE5, Pelvic floor dysfunction, ATC, Hypotension, Itraconazole, International, Man, European, Headache, Ageing, Language, Blood, CGMP, Mouth, Eye, Pulmonary hypertension, Erectile dysfunction, Stroke, Kidney, Kidney disease, Angina, Ketoconazole, HIV, Ritonavir, Tablet, Indinavir, Select, Committee, Patient, Penis, Liver disease, Risk management, Anatomy, Medicine, Dialysis, IIA, Diabetes, CHMP, Medical device

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering

Retrieved on: 
Friday, December 15, 2023
Suite, Marketing, Sale, Software, Form, Attention, Prospectus, GROW, Equity capital markets, Security (finance), Venture, Erectile dysfunction

The offering is expected to close on or about December 19, 2023, subject to customary closing conditions.

Key Points: 
  • The offering is expected to close on or about December 19, 2023, subject to customary closing conditions.
  • Boustead Securities, LLC is acting as the sole underwriter for the offering.
  • The offering is being made only by means of a prospectus.
  • A copy of the final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov .

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

Retrieved on: 
Wednesday, December 13, 2023
Liver, Marketing, Hypogonadism, Risk, PRIME, FDA, TRT, WCS, Telehealth, Absorption, Fatigue, Health, Softgel, Site, SHGB, Conditional sentence, Obesity, Lymphatic system, DTC, Patient, Endocrine system, Erectile dysfunction, Pharmaceutical industry

KYZATREX, a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions, is one of only three FDA approved TRT treatments that is delivered orally--as opposed to the traditional, invasive, and inconvenient injection-based drug delivery protocol. KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.

Key Points: 
  • KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
  • Testosterone deficiency is often first recognized through symptoms of fatigue or low energy, decreased sex drive, lower muscle mass and many other negative downstream impacts.
  • PRIME, powered by KYZATREX, can help men restore Testosterone to normal levels and improve how they feel.
  • KYZATREX marks a shift in the treatment paradigm and a meaningful opportunity for patients seeking to restore optimal testosterone levels.

Mangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin America

Retrieved on: 
Wednesday, December 6, 2023
Marketing, EFI, ED, Oracle, Research, Certification, USD, Allianz, RDT, Pharmacy, OTC, Erectile dysfunction, Sony

Dallas, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce the establishment of its subsidiary, MangoRx Mexico, which will act as the lynchpin of the Company’s Mexican and expanded Latin American sales strategies for its Mango ED products.

Key Points: 
  • The Company has engaged one of the largest international law firms, Diaz Reus International Law Firm, to establish its subsidiary presence in Mexico.
  • “This has enormous implications for our growth trajectory going forward for several important reasons,” noted Jacob Cohen, MangoRx’s Co-Founder and CEO.
  • “First, ED medications - such as branded and generic Viagra (Sildenafil) and Cialis (Tadalafil) - are available to consumers over-the-counter in Mexico.
  • “The path from here to full launch of Latin American sales for MangoRx products is a top priority, and we look forward to providing updates very soon.”

Aspargo Laboratories Inc. Announces Completion of Dosing of All Subjects in Sildenafil Oral Suspension Bioavailability Study and Initiation of Dosing in Companion Food-Effect Study

Retrieved on: 
Tuesday, December 5, 2023
Male, ED, Fed, Absorption, Plasma, Sildenafil, Prevalence, Fasting, Tablet, University, Patient, Erectile dysfunction, Pharmaceutical industry

In addition, today the Company announced the initiation of dosing of 38 subjects in two cohorts in the Company’s food effect study, comparing the amount of active drug in plasma after administration of a single oral dose of Sildenafil Oral Suspension (ASP-001) under fasting and fed (following a meal) conditions.

Key Points: 
  • In addition, today the Company announced the initiation of dosing of 38 subjects in two cohorts in the Company’s food effect study, comparing the amount of active drug in plasma after administration of a single oral dose of Sildenafil Oral Suspension (ASP-001) under fasting and fed (following a meal) conditions.
  • We look forward to providing top-line data from both studies in early 2024.”
    Sildenafil Oral Suspension is an oral liquid suspension of sildenafil citrate administered via a metered-dose pump that dispenses 12.5 mg of sildenafil per actuation.
  • Aspargo uses a metered-dose container that delivers the precise amount of sildenafil citrate per actuation based on patient need.
  • The discreet and easy-to-carry oral formulation allows the user to customize dosing, with physician direction, and avoid pill splitting or crushing common with the traditional tablet medication.

Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider

Retrieved on: 
Wednesday, November 29, 2023
Paramount, Marketing, Partnership, Physician, Male, FDA, Health, CLIA, Patient, Joint Commission, Erectile dysfunction, Pharmaceutical industry

Dallas, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product branded ‘GROW’ and erectile dysfunction (ED) drug branded “Mango,” today announced that it has selected TRYBE Labs to provide its customers with a minimally invasive FDA approved at-home blood collection device and testing services as the Company seeks to further expand its product lines requiring blood tests and results reviewed by physicians.

Key Points: 
  • Using innovative, FDA approved at-home blood collection technology, TRYBE Labs is a CLIA certified and Joint Commission accredited laboratory that provides a direct-to-consumer product which includes an easy-to-use collection kit, full range of testing, and physician-read results for male health and performance evaluation - including hormone, thyroid and vitamin levels.
  • “TRYBE Labs offers a unique, innovative, convenient, and minimally invasive approach for blood collection and testing along with fast result turnaround times (in as little as 72 hours) for patients across the United States.
  • “TRYBE Labs was built by men, for men,” said Lewis Scalione, Founding Partner, TRYBE Labs.
  • By putting the power of information and cutting-edge technology directly into their hands, we are making healthcare more accessible to all who need it.”

CLS Americas Selects Quest International to Provide Aftermarket Service and Logistics Operations for TRANBERG Laser Ablation System

Retrieved on: 
Tuesday, November 28, 2023
ED, Quest International, Risk, FLA, Service, Quest, Prostate cancer, Original equipment manufacturer, Urinary incontinence, CLS, Growth, Diagnosis, Urology, Erectile dysfunction, Medical imaging

LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has selected Quest International , a global aftermarket technical service provider to OEMs, to provide Service and Logistics Operations for the US market.

Key Points: 
  • LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has selected Quest International , a global aftermarket technical service provider to OEMs, to provide Service and Logistics Operations for the US market.
  • Under the agreement, Quest will provide end to end white glove service management including field services, depot repair, and warehousing and logistics support for CLS’s TRANBERG Thermal Therapy System , a 510(k) medical device for soft tissue ablation.
  • The CLS TRANBERG System provides safe and effective focal laser ablation of low-to-medium risk prostate tumors, while also preserving healthy tissue to minimize the risk of unwanted side effects such as ED and urinary incontinence.
  • “CLS Americas is very pleased to partner with Quest International and its excellent reputation and expertise in all aspects of aftermarket service and logistics operations,” stated Michael Magnani, president of CLS Americas.

Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

Retrieved on: 
Monday, November 13, 2023
Cream, Arousal, Behavioral medicine, International Society, Woman, Food, Medical director, Ageing, Gynaecology, Orgasm, Female sexual arousal disorder, OBGYN, FDA, CCD, Menopause, FACOG, North American Menopause Society, Obstetrics, Female, NCMP, Erectile dysfunction, NAMS, Birth control, MD

“The comprehensive Phase 2b RESPOND study data represent an important milestone in the field of female sexual dysfunction,” said Dr. Andrew Goldstein, Medical Advisor for Daré Bioscience and former President of The International Society for the Study of Women's Sexual Health (ISSWSH).

Key Points: 
  • “The comprehensive Phase 2b RESPOND study data represent an important milestone in the field of female sexual dysfunction,” said Dr. Andrew Goldstein, Medical Advisor for Daré Bioscience and former President of The International Society for the Study of Women's Sexual Health (ISSWSH).
  • Sildenafil Cream is an investigational, proprietary topical cream formulation specifically designed to be used on-demand at the time of sexual activity to increase blood flow to the genital tissue in women.
  • "These additional data from the Phase 2b RESPOND study, which demonstrated improvements in a broader population of women, underscore the meaningful potential for Sildenafil Cream in women's sexual health.
  • There is a critical unmet need for a safe, effective and ‘on demand' solution to difficulties with sexual arousal."

Public advisory - Unauthorized injectable drug products sold online by Canlab Research may pose serious health risks

Retrieved on: 
Wednesday, December 13, 2023
Sale, Peptide, Infant, Abdominal pain, Headache, Triptorelin, Patient, Oxytocin, Ovulation, Water intoxication, Pharyngitis, Infection, Oxygen, Background, Amniotic fluid, Erectile dysfunction, Lethargy, Pharmacy, Vomiting, Placenta, Osteoporosis, Safety, Fertility, Argyreia nervosa, Asphyxia, Canada Border Services Agency, DIN, Pelvimetry, Uterine rupture, Nursing, Drug identification number, Toxemia, Health, Diarrhea, Bleeding, Health Canada, Nausea, Chronic pain, Plasma protein binding, Fetus, Allergy, Somnolence, Anaphylaxis, Endometriosis, Depression, Hormone, Risk, Constipation, History, Premature, Long QT syndrome, Stroke, Seizure, Pain, Natural product, Drug, Upper respiratory tract infection, NPN, Prostate cancer, Prescription drug, Pituitary gland, Dietary supplement

Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.

Key Points: 
  • Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.
  • The products are promoted as peptides and are sold online via Canlab Research websites including www.canlabresearch.com and www.canlab.net .
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • This is not a complete description of all the unauthorized health products advertised and sold on the Canlab Research websites.

CLS Americas States KASRAEIAN Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation

Retrieved on: 
Thursday, November 9, 2023
FDA, Erectile dysfunction, CLS, Temperature, FLA, Urology, Physician, Organization, Prostate cancer, FACS, Prostate, Microsoft mobile services, Cancer, Patient, Diagnosis, Urinary incontinence, Medical imaging

LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that KASRAEIAN Urology located in Jacksonville, FL, will begin treating prostate cancer patients using the TRANBERG™ Thermal Therapy System to provide focal laser ablation treatments.

Key Points: 
  • LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that KASRAEIAN Urology located in Jacksonville, FL, will begin treating prostate cancer patients using the TRANBERG™ Thermal Therapy System to provide focal laser ablation treatments.
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “We look forward to adding the TRANBERG focal laser ablation treatment option for our low-to-intermediate risk prostate cancer patients.
  • It allows them to gain access to our image-guided TRANBERG focal laser ablation system without any capital equipment expense,” said Michael Magnani, president of CLS Americas.